Regenxbio rises after report FDA to reverse rejection of rare-disease gene therapy
22/06/2026 12:19
BUZZ-Regenxbio rises after report FDA to reverse rejection of rare-disease gene therapy ** Shares of drug developer Regenxbio RGNX.O rise 7.8% to $8.41 premarket
** U.S. FDA to reverse rejection of RGNX's rare-disease gene therapy, Navsunli, Wall Street Journal reports
** Co plans to refile its application in Q3 after a formal meeting with the FDA expected in July, the reports says
** FDA had rejected the initial application in February, citing concerns around the study and asking for a new trial with placebo patients
** Reuters could not immediately reach Regenxbio for comment outside regular business hours
** As of last close, RGNX down 45.8% YTD
(Reporting by Kunal Das in Bengaluru)